Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, are pleased to announce they
Avacta Plc (AIM:AVCT) Drug Development Partnership with Glythera
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug
